Baicalein is a novel TLR4‐targeting therapeutics agent that inhibits TLR4/HIF‐1α/VEGF signaling pathway in colorectal cancer
Guardado en:
Autores principales: | Minting Chen, Keying Zhong, Jincheng Tan, Mingjing Meng, Chok Mei Liu, Baisen Chen, Chunhua Huang, Hoi Leong Xavier Wong, Zhaoxiang Bian, Tao Su, Hiu Yee Kwan |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Wiley
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/10246f69f8814e759eecba1a97cdea14 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Hyperexpression of TLR2 and TLR4 in patients with ischemic stroke in acute period of the disease
por: L. V. Gankovskaya, et al.
Publicado: (2020) -
Toll-like receptor (TLR2 and TLR4) polymorphisms and chronic obstructive pulmonary disease.
por: Simona E Budulac, et al.
Publicado: (2012) -
TLR2 and TLR4 in Parkinson’s disease pathogenesis: the environment takes a toll on the gut
por: Anastazja M. Gorecki, et al.
Publicado: (2021) -
Interaction of Opioids with TLR4—Mechanisms and Ramifications
por: Mai Mahmoud Gabr, et al.
Publicado: (2021) -
Toll-like receptor (TLR) 2 and TLR4 differentially regulate doxorubicin induced cardiomyopathy in mice.
por: Yonggang Ma, et al.
Publicado: (2012)